Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up.
Aged
Aged, 80 and over
Bone Density Conservation Agents
/ administration & dosage
Diphosphonates
/ administration & dosage
Disease Progression
Drug Administration Schedule
Female
Femoral Fractures
/ chemically induced
Follow-Up Studies
Fractures, Stress
/ chemically induced
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Osteoporosis
/ drug therapy
Radiography
Retrospective Studies
Withholding Treatment
Atypical femoral fracture management
Bisphosphonate
Conservative management
Insufficiency fracture
Osteoporosis treatment
Prophylactic surgery
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
04
02
2019
accepted:
19
06
2019
pubmed:
23
8
2019
medline:
1
7
2020
entrez:
23
8
2019
Statut:
ppublish
Résumé
Understanding the natural history of lateral femoral stress fractures helps to guide their management. Improvement in their radiographic characteristics is rare. Progression was generally sequential, most developing an incomplete fracture line before fracture displacement. Stopping bisphosphonates decreased the fracture rate, a feasible management option for lesions without incomplete fracture lines. Retrospective study evaluating the natural history of lateral femoral stress fractures (FSF) by serial radiography over a variable period of time in a cohort of patients treated for some time with bisphosphonates for osteoporosis, whilst also identifying the fracture response in cases where bisphosphonates were discontinued. The radiographs of 76 consecutive patients (92 femurs) with 161 FSF were reviewed to document their change over time. Femurs were classified into the following: A-normal, B-focal cortical thickening, C-dreaded black line and D-displaced fracture. Bisphosphonate history was recorded. 66.5% FSF showed group stability between the first and last radiographs: group B (79.1%), group C (45.7%). 28.6% progressed, mostly following an ordered sequence starting from group A, progressing to B, then C, before culminating in D. Progression rate was as follows: A-100% (11/11), B-18.3% (21/115), C-40% (14/35). Regression in FSF was uncommon-5.6% (8/161). 34.8% (32/92) sustained displaced fractures. Kaplan-Meier analysis showed statistically significant difference between the groups; median survival (95% CI): A-4189 (-), B-3383.0 (-), C-1807 (0.0-3788.6) and progression to displaced fracture when bisphosphonate had been stopped for at least 6 months. The group without recent bisphosphonates had a lower group progression rate (17.1%, 12/70). Nevertheless, 10.9% (5/46) progressed to displaced fracture. This group also had the highest proportion of stable (77.1%, 54/70) and regressive lesions (5.7%, 4/70). In FSF, there is natural progression from normal bone, to focal cortical thickening, to dreaded black line and eventually to displaced fracture. Most lesions persist, remaining static or progressing, especially if a dreaded black line is present and bisphosphonates are continued. Regression is uncommon and more frequent when bisphosphonates are discontinued. Despite stopping bisphosphonates, there remains a 10.9% risk of progression to displaced fracture.
Identifiants
pubmed: 31435684
doi: 10.1007/s00198-019-05067-7
pii: 10.1007/s00198-019-05067-7
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2417-2428Références
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301. https://doi.org/10.1210/jc.2004-0952
doi: 10.1210/jc.2004-0952
pubmed: 15598694
Koh JSB, Goh SK, Png MA, Ng ACM, Howe TS (2011) Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singap Med J 52:77–80
Kwek EBK, Goh SK, Koh JSB, Png MA, Sen HT (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231. https://doi.org/10.1016/j.injury.2007.08.036
doi: 10.1016/j.injury.2007.08.036
pubmed: 18222447
Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350. https://doi.org/10.1097/BOT.0b013e318172841c
doi: 10.1097/BOT.0b013e318172841c
pubmed: 18448990
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, Van Der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 29:1–23. https://doi.org/10.1002/jbmr.1998
doi: 10.1002/jbmr.1998
pubmed: 23712442
Isaacs JD, Shidiak L, Harris IA, Szomor ZL (2010) Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res 468:3384–3392. https://doi.org/10.1007/s11999-010-1535-x
doi: 10.1007/s11999-010-1535-x
pubmed: 20809164
pmcid: 2974861
Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, McKoy JM, Omar I, Belknap SM, Garg V, Hahr AJ, Samaras AT, Fisher MJ, West DP, Langman CB, Stern PH (2013) Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts. J Bone Jt Surg-Am 95:297–307. https://doi.org/10.2106/JBJS.K.01181
doi: 10.2106/JBJS.K.01181
Koh JSB, Goh SK, Png MA, Kwek EBK, Sen HT (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 24:75–81. https://doi.org/10.1097/BOT.0b013e3181b6499b
doi: 10.1097/BOT.0b013e3181b6499b
pubmed: 20101130
Png MA, Koh JSB, Goh SK, Fook-Chong S, Sen HT (2012) Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. Am J Roentgenol 198:869–877. https://doi.org/10.2214/AJR.11.6794
doi: 10.2214/AJR.11.6794
Saleh A, Hegde VV, Potty AG, Schneider R, Cornell CN, Lane JM (2012) Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J 8:103–110. https://doi.org/10.1007/s11420-012-9275-y
doi: 10.1007/s11420-012-9275-y
pubmed: 23874247
pmcid: 3715620
Min B-W, Koo K-H, Park Y-S, Oh C-W, Lim S-J, Kim J-W, Lee K-J, Lee Y-K (2016) Novel scoring system for identifying impending complete fractures in incomplete atypical femoral fractures. J Clin Endocrinol Metab 102:jc2016–jc2787. https://doi.org/10.1210/jc.2016-2787
doi: 10.1210/jc.2016-2787
Min A, Chan VWY, Aristizabal R, Peramaki ER, Agulnik DB, Strydom N, Ramsey D, Forster BB (2017) Clinical decision support decreases volume of imaging for low back pain in an urban emergency department. J Am Coll Radiol 14:889–899. https://doi.org/10.1016/j.jacr.2017.03.005
doi: 10.1016/j.jacr.2017.03.005
pubmed: 28483544
Mohan PC, Howe TS, Koh JSB, Png MA (2013) Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy. Eur Radiol 23:222–227. https://doi.org/10.1007/s00330-012-2587-y
doi: 10.1007/s00330-012-2587-y
pubmed: 22814830
Lee Y-KK, Ha Y-CC, Kang BJ, Chang JS, Koo K-HH (2013) Predicting need for fixation of atypical femoral fracture. J Clin Endocrinol Metab 98:2742–2745. https://doi.org/10.1210/jc.2012-4322
doi: 10.1210/jc.2012-4322
pubmed: 23671316
Koh A, Guerado E, Giannoudis PV (2017) Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Jt J 99B:295–302. https://doi.org/10.1302/0301-620X.99B3.BJJ-2016-0276.R2
doi: 10.1302/0301-620X.99B3.BJJ-2016-0276.R2
Egol KA, Park JH, Rosenberg ZS, Peck V, Tejwani NC (2014) Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res 472:2728–2734. https://doi.org/10.1007/s11999-013-2963-1
doi: 10.1007/s11999-013-2963-1
pubmed: 23604648
Ha YC, Cho MR, Park KH, Kim SY, Koo KH (2010) Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 468:3393–3398. https://doi.org/10.1007/s11999-010-1583-2
doi: 10.1007/s11999-010-1583-2
pubmed: 20865463
pmcid: 2974881
Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM (2011) Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 96:1627–1632. https://doi.org/10.1210/jc.2010-2520
doi: 10.1210/jc.2010-2520
pubmed: 21430030
Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K (2015) Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 86:100–107. https://doi.org/10.3109/17453674.2015.1004149
doi: 10.3109/17453674.2015.1004149
pubmed: 25582459
pmcid: 4366670
Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, McGlynn EA, Gozansky WS (2018) Bisphosphonate drug holiday and fracture risk: a population-based cohort study. J Bone Miner Res 33:1252–1259. https://doi.org/10.1002/jbmr.3420
doi: 10.1002/jbmr.3420
pubmed: 29529334
Zanchetta MB, Diehl M, Buttazzoni M, Galich A, Silveira F, Bogado CE, Zanchetta JR (2014) Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur. J Bone Miner Res 29:999–1004. https://doi.org/10.1002/jbmr.2107
doi: 10.1002/jbmr.2107
pubmed: 24115250
Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565. https://doi.org/10.1210/jc.2009-1947
doi: 10.1210/jc.2009-1947
pubmed: 20173017
Watts N, Bilezikian J, Camacho P, Greenspan S, Harris S, Hodgson S, Kleerekoper M, Luckey M, McClung M, Pollack R, Petak S (2010) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16:1–37. https://doi.org/10.4158/ep.16.s3.1
doi: 10.4158/ep.16.s3.1
pubmed: 21224201
pmcid: 4876714
Compston JE, Bilezikian JP (2012) Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res 27:240–242. https://doi.org/10.1002/jbmr.1494
doi: 10.1002/jbmr.1494
pubmed: 22271395
Bindon B, Adams W, Balasubramanian N, Sandhu J, Camacho P (2018) Osteoporotic fractures during bisphosphonate drug holiday. Endocr Pract 24:163–169. https://doi.org/10.4158/EP171975.OR
doi: 10.4158/EP171975.OR
pubmed: 29144808
Banffy MB, Vrahas MS, Ready JE, Abraham JA (2011) Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res 469:2028–2034. https://doi.org/10.1007/s11999-011-1828-8
doi: 10.1007/s11999-011-1828-8
pubmed: 21350886
pmcid: 3111775
Egol KA, Park JH, Prensky C, Rosenberg ZS, Peck V, Tejwani NC (2013) Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures. J Orthop Trauma 27:331–335
doi: 10.1097/BOT.0b013e31827240ae
Oh C-W, Oh J-K, Park K-C, Kim J-W, Yoon Y-C (2013) Prophylactic nailing of incomplete atypical femoral fractures. SciWorld J 2013:450148. https://doi.org/10.1155/2013/450148
doi: 10.1155/2013/450148
Weil YA, Rivkin G, Safran O, Liebergall MFA (2011) The outcome of surgically treated femur fractures associated. J Trauma 71:186–190. https://doi.org/10.1097/TA.0b013e31821957e3
doi: 10.1097/TA.0b013e31821957e3
pubmed: 21610533
Teo BJX, Koh JSB, Goh SK, Png MA, Chua DTC, Howe TS (2014) Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone Jt J 96 B:658–664
doi: 10.1302/0301-620X.96B5.32887
Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG (2012) Bisphosphonate-associated femur fractures have high complication rates with operative fixation trauma. Clin Orthop Relat Res 470:2295–2301. https://doi.org/10.1007/s11999-012-2412-6
doi: 10.1007/s11999-012-2412-6
pubmed: 22669553
pmcid: 3392377